Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…
DBV Technologies to Participate in Upcoming EAACI Congress 2025
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI…
